Clinical Trial Update: A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the withdrawal of a Phase I/II study evaluating vorinostat added to pemetrexed-cisplatin as first-line therapy for malignant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• Vorinostat (vorinostat)

Snippet

Sponsor: University College, London | Conditions: Malignant Pleural Mesothelioma | Phase 1, Phase 2 | Status: WITHDRAWN